Between-laboratory agreement in the UK EQAS for maternal serum alphafetoprotein has improved steadily since 1976 and the geometric coefficient of variation is now 8 to 9°,{, at levels of 50 to 150 kU/L. The usc of a common standard and commercial assay kits appear to have contributed to this trend. Within-laboratory performance is also generally good. about 50% of participants maintain a bias of less than 5%. together with a scatter of the bias of less than 10%. These data indicate that the quality of assay performance is adequate for the requirements of screening programmes for open neural tube effects. The improvement in laboratory performance is such that betweenlaboratory agreement is better expressed in kU/L than as multiples of the median. Errors in interpretation of clearly normal or abnormal results appear to be rare (0·4 %), and contribute little to overall false positive and negative rates. However. they assume significance as most arc due to avoidable errors.
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Antenatal screening for neural tube defects (NTDs) was introduced in the late 1970's in parts of the United Kingdom (UK), and has since become more widely established following the recommendations of the Working Group on Screening for Neural Tube Defects' for a nationally coordinated screening service. Screening is based on the measurement of maternal serum alphafetoprotein (ms AFP) at 16 to 18 weeks to identify those women with high levels who are selected for ultrasonography and amniocentesis, so that NTD can be diagnosed in utero.
The effectiveness of such a screening programme depends on the quality of ms AFP measurements in screening laboratories. Recognising this, the Working Group' recommended that laboratories should participate in a National Quality Control Scheme for ms AFP, to ensure that performance did not fall below an acceptable standard. The scheme, now called the UK External Quality Assessment Scheme (UK EQAS), was established in 1976. and the early experience has been described. I-3 Correspondence: J Seth.
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This report summarises performance in the scheme from 1980 to 1987. a period during which there has been an increase in the number of laboratories performing the assay and in the range of assay methods available. The data are examined particularly for trends in quality of performance. and for areas where difficulties remain. The implications of the data for the efficiency of the national screening service are also considered.
Materials and methods

OPERATION Of THE SCHEME
The UK EQAS for ms AFP is one of a range of schemes supported by the UK Government Health Departments, and the philosophy and principles of their operation have been described." Laboratories participate on a confidential basis, and arc referred to by code number only. Participation is voluntary. but is strongly encouraged. and is free to UK National Health Service and university laboratories.
At the present time samples arc prepared from sera collected by the Blood Transfusion
Results
TRENDS IN PARTICIPATION AND METHODS
USED
When the scheme started in 1976 there were 23 laboratories participating; these were mostly those involved in the early evaluation of IDS AFP screening. As a result of expansion in the screening services, the number of laboratories is now 103, and Fig. 1 shows the recent trend. Most of participants use radioimmunoassay (RIA); these are equally divided between 'in-house' and commercial kit methods, and the numbers using these two methods have remained essentially unchanged for several years. Use of commercial kits for immunometric methods, both isotopic and non-isotopic is, however, clearly increasing. Table 1 gives details of the methods used at present.
DATA ANALYSIS
Participants are asked to return results, expressed in kU/L BS 721227, within 3 weeks for inclusion in the monthly report, which is issued with the subsequent distribution of samples. The method of data analysis underwent some changes during the early years of the scheme, but has remained unchanged since 1980. The statistics and indices of performance calculated are:
All laboratory trimmed geometric mean (A L TM). This isthe geometric mean of all results on each sample, after excluding greater than and less than results. The results are then trimmed (5% lowest and 5% highest removed) using the procedure of Healy? to increase robustness of the sample statistics and to identify outlier results more reliably. The ALTM for each sample is used as its target value.
Within-sample, between-laboratory agreement. This is estimated as the geometric coefficient of variation (GCV)l! of all results on each sample, calculated as above, allowance being made for the trimming. 7 Between-laboratoryoutliers. These are results more than three geometric standard deviations (GSD) from the ALTM.
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Service from patients undergoing therapeutic Cumulativelaboratory bias (BIAS). This is the venesection for polycythaemic rubra vera. Indi-geometric mean of the ratios of the laboratory vidual collections are tested and confirmed as result to the ALTM for all usable samples over being negative for Hepatitis Bs antigen and the six most recent distributions (minimum 10, Human Immunodeficiency Virus (HIV) anti-maximum 30 samples). The deviations are body." The sera are stabilised by the addition of trimmed, as described above," and the mean sodium azide (0·1%) and stored at -3l)OC bias is expressed as a percentage difference pending pooling to provide sufficient volumes from 100. for distribution. Pools are filtered to sterility Cumulative laboratory variability of the bias (0·2 11m) under nitrogen at pressure (1 bar).
(VAR). This is the GCV of the ratios of the Cord serum or the AFP British Standard (BS laboratory result to the ALTM, based on the 10 721227t'is then added to give concentrations in to 30 samples described above, allowance being the range 30 to 300 kU/L. Aliquots (1·0 mL) of made for the trimming." VAR describes the the pools are dispensed into 3 mL plastic tubes, consistency of the laboratory's deviation from which are stored at -3l)OC pending distribution. the ALTM; it reflects intra-and inter-assay Participants are sent five coded serum samples precision, but also reflects any concentration or monthly by first class mail at ambient tempera-pool-related changes in bias that may exist. ture. The samples reach their destinations
As a stimulus towards improving performusually within 24 h, and always within 48 h.
ance, performance criteria were set on the basis These procedures for sample preparation are of the BIAS and VAR achievable in the broadly similar to those employed in the early majority of laboratories. The criteria were set years of the scheme, the important differences by an independent panel of experts, and during being that before 1983, samples often com-much of the period reviewed were: 'desirable prised individual donations of serum from performance' -BIAS<±5%, VAR<lO%, normal men and non-pregnant women, and 'tolerable performance' -BIAS 5-15%, VAR pooled pregnancy sera. In addition, samples 10-15%; 'unacceptable performance' issued before 1986 were not filtered to sterility, -BIAS>15%, VAR> 15%. In the light of nor treated with azide.
improved performance, the criteria for BIAS were tightened in 1986 to 'tolerable' -5-10%, 'unacceptable-->10%. Other aspects of performance assessed included promptness in return of results, and interpretation of the ms AFP level in terms of whether or not the laboratory would recommend further investigation. to report within the reporting deadline of 3 weeks. and only 3% failed to return at all; in some cases this was due to temporary assay difficulties. Table 2 shows the rate at which laboratories returned results to the EQAS organising centre, Only about 10% of laboratories failed ACCURACY AND REPRODUCIBILITY OF THE TARGET VALUE These were assessed by the following criteria: (a) agreement between the prepared concentration and the target value (ALTM) of pools of sera from men or non-pregnant women supplemented with BS 72/227, (b) linearity of ALTM on dilution of cord serum with normal male serum, and (c) reproducibility of the target value between distributions. Figure 2 shows the agreement over a wide OVERALL BETWEEN-LABORATORY AGREEMENT Figure 3 shows the within-sample, betweenlaboratory agreement of all laboratories since 1980. There has been a trend towards improved agreement in the concentration range of
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Of 20 pools distribution more than once in 1986, none showed a difference in ALTM on repeat distribution of more than 3%. range of concentrations between the amount of AFP (BS 72/227) added to sera from normal men or non-pregnant women and the ALTM. Although agreement is good, the ALTM tends to be slightly lower than the added concentrations at high levels (> ISO kU/L), and higher at low concentrations « 100 kU/L). Overall, the agreement between the ALTM and the prepared concentrations has remained satisfactory over the years 1980-87 (Table 3 ). There is a linear relationship between the ALTM and the volume of cord serum added over the concentration range 20-60 kU/L. The ALTM value shows good stability between successive dis- greatest importance for NTD screening (50-150 kU/L), where the GCV is at present between 8 and 9%. Agreement is, however, less good at lower concentrations; the recent increase in GCV is due to greater between-laboratory scatter on a few samples only, and may not indicate the underlying trend. For distributions up to late 1984, participants were also asked to report results as multiples of the median (MOM) for a given gestational age. Figure 4 compares the between-laboratory GCV for results as kU/L, and as MOM; between-laboratory agreement was consistently poorer at all gestational ages for results expressed as MOM. Fig. 6 . All method groups have a median BIAS within 3% of the ALTM. Data for the group using the non-isotopic immunometric assays must be interpreted with caution, as each of the three assays represented in this group is used by only a small number of laboratories. The negative bias and high VAR of the LKB DELFIA method are due to low results which it gave on a series of samples prepared from one pool, and which were not observed with other samples. The performance of this method otherwise appeared satisfactory. VAR is lowest among the group using the NETRHA method, and highest among non-isotopic assays. Assays for maternal serum alphafetoprotein 315 tently achieved the desirable levels of BIAS, and of VAR; just over 50% achieved desirable performance for both. Conversely, a small percentage of laboratories performed poorly, although these were not always the same laboratories from year to year. The recent increase in proportion of the laboratories with unacceptable bias is a result of the negative bias of some of the newer immunometric methods. Between 1 and 2% of the results reported on each sample were between-laboratory outliers. About 40% of participants reported one to three outlier values from the 60 results that each reported yearly, 10% reported four to six outliers and about 5% reported seven or more outliers. The laboratories reporting outliers were, with few exceptions, not the same from year to year; the usual pattern was of sporadic occurrence of outliers, although the overall pattern of outlier reporting has not changed over the period reviewed. whether or not, given a gestational age for the sample, they would recommend further action (i.e. repeat ms AFP test). Figure 8 shows the action recommended in relation to the AFP level given an assumed gestational age of 17 weeks. There was a wide concentration range (65-100 kU/L) over which interpretation differed between laboratories, reflecting local differences in the action limits applied. The pattern of response seen at 16 and 18 weeks was similar, but with the lines denoting the responses shifted approximately 10 kU/L to the left and right, respectively. However, on the unequivocally normal and definitely abnormal samples, 0·4% of results were misinterpreted; these were approximately equally divided between false positives and false negatives. The majority (60%) of these errors were betweenlaboratory outliers, often in a pattern suggesting incorrect sample identification or result reporting, rather than an analytical error. Errors due to incorrect interpretation of an analytically satisfactory result appeared to be rare.
INTERPRETATION OF RESULTS
Ninety per cent of participants responded to the invitation to interpret their results in terms of
Discussion
The data rresented here extend the previously published . 3 accounts of the UK EQAS for ms AFP. Together, these reports provide a continuous record over 11 years of the quality of performance of laboratories providing a national screening service for NTD. Three aspects of the data need to be considered: (I) the evidence that the UK EQAS provides a valid indication of laboratory performance, (2) the adequacy of performance of laboratories and methods in a purely analytical sense, and (3) the implications of the quality of performance for the efficiency of the screening service. These three points will be considered in tum.
VALIDITY OF PERFORMANCE ASSESSMENT IN EQAS
The important requirements here are that the sample material distributed in the EQAS has identical or at least similar properties to the samples normally assayed, and that the performance indices are valid. Although pregnancy sera are the most appropriate samples, and were used in the early years of the scheme, the demand for larger volumes of serum to meet the needs of the increasing number of participants, and the more recent need to test individual donations for HIV antibody, 5 have prevented this approach. The samples distributed at present, which are pooled sera from men or non-pregnant women, with added cord serum or purified AFP BS 721227 may not fully represent performance in individual pregnancy sera for two reasons. Firstly, recovery of BS 721227 has been reported to differ between individual donations of normal serum from men.' presumably due to the effects of differences in serum matrix. The use of pooled sera will obscure such intersample differences, and give an optimistic view of performance. Secondly, there might be qualitative differences between endogenous AFP in pregnancy serum, and exogenous AFP in the EQAS samples. This could be due, for example, to the presence of aggregates which might have differing potencies in different assays. These reservations apart, the data show that the target value (ALTM) is accurate and stable over a wide range of concentrations and has remained so over many years (Table 3) . Data collected in 1978 2 showed similarly good accuracy of the consensus mean. These are important points to establish and to maintain under regular review, as the credibility of any EQAS is crucially dependent on the validity of the target value.
QUALITY OF ANALYTICAL PERFORMANCE
An important and encouraging observation is the steady improvement in between-laboratory agreement with time (Fig. 3) . The present position can be contrasted with that at the time of the UK Collaborative Study in 1977,10 which revealed marked disagreement between results expressed in ng/mL; this was not unexpected in view of the lack of a common standard. Between-laboratory agreement was also unsatisfactory in the first 2 years of the UK EQAS, even though results were by then being expressed in terms of BS 721227-the betweenlaboratory CV was 30% initially, but fell to about 15%. 2 The improvement continued during 1980 and 81,3 and was sustained to 1984, after which year the GCV has remained steady at about 8 to 9% for samples in the 50-ISO kU/L range. Overall, these data show a substantial improvement in between-laboratory agreement; the 95% confidence limits for a sample of 100 kU/L for example, would have been approximately 60-160 kUlL 10 years ago, but are now 8()-) 20 kU/L. Several factors have contributed to this trend. The use of a common standard (BS These data almost certainly underestimate the response time for clinical samples, as EQAS samples might be accorded a lower priority in urgency of analysis, and reports on EQAS samples are subject to postal delays which would not affect reports on clinical samples, especially where the results are abnormal.
At the time of the UK Collaborative Study!" inaccuracy was a major impediment to achieving a consensus on the cut-off levels to be used. This was overcome by the use of MOMs, which require only relative accuracy. A report of a 1978workshop'" further stated that, for screening purposes, only relative accuracy was required, and that absolute accuracy was unnecessary. It is somewhat surprising, therefore, to find that the data from the scheme show that the quality of analytical performance has improved to such an extent that the use of MOM is no longer necessary to achieve betweenlaboratory comparability. Indeed, use of the MOM has a detrimental effect on betweenlaboratory agreement ( Fig. 4) , which might reflect sources of error such as incorrect estimation of median values, and errors in the calculation of MOM itself. Thus, improved interpretive consensus might be anticipated if cut-offs were defined in terms of kUIL, rather than MOM.
Furthermore, the data indicate that most laboratories (70%) maintain a bias within 5%, and that of laboratories providing a screening service only a few (5%) have bias greater than 10%. Thus, laboratory bias is unlikely to affect the sensitivity and specificity of screening.
The effect of imprecision on the sensitivity and specificity of ms AFP screening was also discussed in the report of the 1978 workshop. 13 The recommended limit to 'across batch imprecision' was such that the assay variance should be no more than 25% of the within-week population variance (both expressed on a log scale). Using population data from the UK Collaborative Study, 10 the required standard deviation (log 10 scale) for the assay imprecision is 0·1048, which equals a CV of 24%, or GCV of 27%.
The EQAS data do not, unfortunately, provide a directly comparable measure of imprecision. VAR reflects inter-and intra-assay imprecision, but also includes sources of variance that are pool and concentration dependent-VAR consequently overestimates assay imprecision. Even so, the majority (70%) of laboratories achieve a VAR of less than 10%, 95% achieve a VAR of less than 15%, IMPLICATIONS FOR EFFECTIVENESS OF
SCREENING PROGRAMME FOR NTDS
The need for adequate performance, both in rapidity of reporting, and analytical quality, was stated in the recommendations of the Working Group on Screening for NTDs. I The data presented here show that most laboratories report on the EQAS samples between I and 2 weeks after their distribution. The pattern does not appear to differ from that observed in the early years of the scheme.' where the best response time was about 5 days, the median II days and the worst 25 days. 72/227) has probably been the most important contributor. The Second International Study on the WHO AFP standardII showed that between-laboratory agreement was improved by using a common standard, rather than a variety of local standards. An additional factor' is the increased use of assay kits. Fig. 5 shows the better between-laboratory agreement achieved among users of the Amersham International RIA kit, compared with users of 'in house' RIAs. These data provide a further example of the benefits of common standards, assay reagents and protocols in securing improved between-laboratory agreement, which has been observed in other EQAS, and has been reviewed elsewhere.'? Given this evidence of good betweenlaboratory agreement, it is not surprising to find that within-laboratory performance is also generally good, 60 to 70% of participants achieving BIAS or VAR within the desirable limits. A less satisfactory aspect of performance, however, is that between-laboratory outliners continue to be reported by many participants. These are potentially the most serious of laboratory errors. Their usual pattern of sporadic occurrence, occasionally affecting all five samples in a distribution, suggests that they may be due to errors in sample identification, or in recording results. On the other hand, among the few laboratories reporting many outliers, method bias often appeared to be the cause.
Although there has been no reduction in the frequency of outlier reporting over the years, it should be noted that the criterion for identifying outliers has become more demanding with the reduction in between-laboratory GCV (Fig.  3) . It is possible, therefore, that there has been a modest improvement in the frequency of outlier reporting when the errors are expressed in absolute terms. and the highest VAR is about 25'Yo •These data suggest that the relatively undemanding criteria recommended in the workshop report':' are comfortably met. and that assay imprecision does not jeopardise the efficiencyof the screening programme.
This conclusion is further supported by the satisfactory response to the assessment of interpretation. The most important source of differences in interpretation is the range of action limits (65 to 100 kU/L at 17 weeks) applied by participants, reflecting local differences in the design of the screening programme. The estimate of the prevalence of misinterpretations (0'4%) on results beyond these limits is not of great quantitative significance in relation to the prevalence of false positives and false negatives (about 3% and 24%, respectively) owing to overlap of the distributions of ms AFP values between normal pregnancies and those with open NTD. However, in interpreting these data it is important to note two points. Firstly. the prevalence of misinterpretations on clearly normal and clearly abnormal results is likely to underestimate the total prevalence. since laboratory errors are more likely to result in misinterpretations when the true result is nearer the cut-off point. Secondly. most of the misinterpretations are the result of betweenlaboratory outliers, which are often avoidable errors. These data underline the need for careful quality control at all stages, including sample reception and reporting. because false abnormal or normal results have an important implication for the patient affected. and even a small additional percentage is to be avoided.
The results from the ms AFP EQAS also provide some guide to the analytical requirements in screening for Down's syndrome. Although relatively few samples at concentrations below the normal median have been distributed, it is clear that between-laboratory agreement deteriorates sharply at low levels ( Fig. 5 ). IRMA methods, however, provide better between-laboratory agreement than RIA at low levels and should provide optimum sensitivity and specificity in screening for Down's syndrome.
